Altimmune announces publication of IMPACT Phase 2b trial data

Altimmune (ALT) announced publication in The Lancet of 24-week efficacy and safety data from the ongoing IMPACT Phase 2b trial of pemvidutide in patients with metabolic dysfunction-associated steatohepatitis in a paper titled “Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis: 24-week results from a multicentre, randomised, double-blind, phase 2b study”. Dr. Mazen Noureddin, M.D., IMPACT trial principal investigator, Professor of Medicine at Houston Methodist Hospital and Co-Chairman of the Board for Summit and Pinnacle Clinical Research will present these data in a late-breaking oral presentation at The Liver Meeting 2025, hosted by the American Association for the Study of Liver Diseases in Washington, D.C. Topline 24-week data from the IMPACT Phase 2b trial were previously announced in June 2025, demonstrating that pemvidutide, Altimmune’s 1:1 glucagon/GLP-1 agonist, achieved statistically significant MASH resolution without worsening of fibrosis, meaningful reductions in fibrosis, liver fat, and clinically relevant weight loss with favorable tolerability. The Lancet publication describes changes across key non-invasive testsfrom blood-based biomarkers, imaging modalities, and combined measures such as FAST score – all markers that offer consistent evidence of fibrosis reduction and improvement in liver inflammation. “As the primary goal of treatment for patients with MASH is to reverse liver fibrosis to prevent progression to cirrhosis and other serious and life-threatening complications, the totality of the 24-week clinical data from the IMPACT trial is very encouraging,” said Dr. Mazen Noureddin. “Given the significant resolution of MASH that occurred after only 24 weeks of treatment, along with strong evidence of anti-fibrotic activity and weight loss, the profile of pemvidutide suggests it has the potential to meaningfully alter the course of this disease.”